Trial Profile
The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Camostat mesilate (Primary)
- Indications COVID 2019 infections; Severe acute respiratory syndrome
- Focus Therapeutic Use
- Acronyms CamoCO-19
- 05 Oct 2021 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.
- 27 Apr 2021 Status changed from active, no longer recruiting to recruiting.
- 27 Apr 2021 Planned End Date changed from 1 May 2021 to 1 May 2022.